nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A7—Vincristine—sarcoma	0.0486	0.12	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0486	0.12	CbGbCtD
Tacrolimus—CYP3A4—Thiotepa—sarcoma	0.048	0.119	CbGbCtD
Tacrolimus—ABCB1—Dactinomycin—sarcoma	0.0385	0.0951	CbGbCtD
Tacrolimus—CYP3A5—Vincristine—sarcoma	0.0365	0.09	CbGbCtD
Tacrolimus—ABCB1—Mitoxantrone—sarcoma	0.0345	0.0851	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—sarcoma	0.0334	0.0824	CbGbCtD
Tacrolimus—ABCB1—Vincristine—sarcoma	0.0237	0.0586	CbGbCtD
Tacrolimus—ABCB1—Etoposide—sarcoma	0.0217	0.0537	CbGbCtD
Tacrolimus—CYP3A4—Mitoxantrone—sarcoma	0.0207	0.051	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—sarcoma	0.0148	0.0366	CbGbCtD
Tacrolimus—CYP3A4—Vincristine—sarcoma	0.0142	0.0351	CbGbCtD
Tacrolimus—CYP3A4—Etoposide—sarcoma	0.013	0.0321	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—sarcoma	0.00888	0.0219	CbGbCtD
Tacrolimus—MTOR—leg—sarcoma	0.00734	0.0562	CbGeAlD
Tacrolimus—MTOR—forelimb—sarcoma	0.00729	0.0558	CbGeAlD
Tacrolimus—MTOR—hindlimb—sarcoma	0.00656	0.0502	CbGeAlD
Tacrolimus—MTOR—appendage—sarcoma	0.00562	0.043	CbGeAlD
Tacrolimus—ABCA5—mammary gland—sarcoma	0.00548	0.042	CbGeAlD
Tacrolimus—ABCA5—myometrium—sarcoma	0.00389	0.0298	CbGeAlD
Tacrolimus—PPP3CA—mammary gland—sarcoma	0.0037	0.0283	CbGeAlD
Tacrolimus—ABCA5—seminal vesicle—sarcoma	0.00352	0.0269	CbGeAlD
Tacrolimus—MTOR—mammary gland—sarcoma	0.00274	0.0209	CbGeAlD
Tacrolimus—PPP3CA—myometrium—sarcoma	0.00263	0.0201	CbGeAlD
Tacrolimus—ABCA5—cardiac atrium—sarcoma	0.00254	0.0194	CbGeAlD
Tacrolimus—FKBP1A—mammary gland—sarcoma	0.00246	0.0188	CbGeAlD
Tacrolimus—PPP3CA—seminal vesicle—sarcoma	0.00237	0.0182	CbGeAlD
Tacrolimus—PPP3CA—hematopoietic system—sarcoma	0.00226	0.0173	CbGeAlD
Tacrolimus—ABCA5—tendon—sarcoma	0.00221	0.0169	CbGeAlD
Tacrolimus—PPP3CA—connective tissue—sarcoma	0.00217	0.0166	CbGeAlD
Tacrolimus—ABCA5—bone marrow—sarcoma	0.00214	0.0164	CbGeAlD
Tacrolimus—PPP3CA—smooth muscle tissue—sarcoma	0.00199	0.0152	CbGeAlD
Tacrolimus—MTOR—myometrium—sarcoma	0.00194	0.0149	CbGeAlD
Tacrolimus—MTOR—embryo—sarcoma	0.00187	0.0143	CbGeAlD
Tacrolimus—ABCA5—testis—sarcoma	0.00183	0.014	CbGeAlD
Tacrolimus—MTOR—seminal vesicle—sarcoma	0.00175	0.0134	CbGeAlD
Tacrolimus—FKBP1A—myometrium—sarcoma	0.00175	0.0134	CbGeAlD
Tacrolimus—ABCA5—liver—sarcoma	0.00173	0.0132	CbGeAlD
Tacrolimus—PPP3CA—cardiac atrium—sarcoma	0.00171	0.0131	CbGeAlD
Tacrolimus—PPP3CA—uterus—sarcoma	0.0017	0.013	CbGeAlD
Tacrolimus—ALB—mammary gland—sarcoma	0.00169	0.0129	CbGeAlD
Tacrolimus—MTOR—hematopoietic system—sarcoma	0.00167	0.0128	CbGeAlD
Tacrolimus—MTOR—connective tissue—sarcoma	0.00161	0.0123	CbGeAlD
Tacrolimus—PPP3CA—lymphoid tissue—sarcoma	0.00159	0.0122	CbGeAlD
Tacrolimus—FKBP1A—seminal vesicle—sarcoma	0.00158	0.0121	CbGeAlD
Tacrolimus—FKBP1A—hematopoietic system—sarcoma	0.0015	0.0115	CbGeAlD
Tacrolimus—PPP3CA—tendon—sarcoma	0.00149	0.0114	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—sarcoma	0.00147	0.0112	CbGeAlD
Tacrolimus—MTOR—skin of body—sarcoma	0.00145	0.0111	CbGeAlD
Tacrolimus—PPP3CA—bone marrow—sarcoma	0.00145	0.0111	CbGeAlD
Tacrolimus—FKBP1A—connective tissue—sarcoma	0.00144	0.011	CbGeAlD
Tacrolimus—ABCA5—lymph node—sarcoma	0.00133	0.0102	CbGeAlD
Tacrolimus—FKBP1A—smooth muscle tissue—sarcoma	0.00132	0.0101	CbGeAlD
Tacrolimus—FKBP1A—skin of body—sarcoma	0.0013	0.00998	CbGeAlD
Tacrolimus—MTOR—uterus—sarcoma	0.00126	0.00964	CbGeAlD
Tacrolimus—PPP3CA—testis—sarcoma	0.00124	0.00947	CbGeAlD
Tacrolimus—ORM1—hematopoietic system—sarcoma	0.00117	0.00898	CbGeAlD
Tacrolimus—MTOR—lymphoid tissue—sarcoma	0.00117	0.00898	CbGeAlD
Tacrolimus—PPP3CA—liver—sarcoma	0.00117	0.00895	CbGeAlD
Tacrolimus—FKBP1A—cardiac atrium—sarcoma	0.00114	0.00871	CbGeAlD
Tacrolimus—FKBP1A—uterus—sarcoma	0.00113	0.00867	CbGeAlD
Tacrolimus—MTOR—tendon—sarcoma	0.0011	0.00844	CbGeAlD
Tacrolimus—MTOR—bone marrow—sarcoma	0.00107	0.00818	CbGeAlD
Tacrolimus—FKBP1A—lymphoid tissue—sarcoma	0.00106	0.00808	CbGeAlD
Tacrolimus—FKBP1A—tendon—sarcoma	0.000992	0.00759	CbGeAlD
Tacrolimus—FKBP1A—bone marrow—sarcoma	0.000961	0.00736	CbGeAlD
Tacrolimus—CYP3A7—liver—sarcoma	0.000961	0.00736	CbGeAlD
Tacrolimus—MTOR—testis—sarcoma	0.000914	0.00699	CbGeAlD
Tacrolimus—PPP3CA—lymph node—sarcoma	0.000897	0.00686	CbGeAlD
Tacrolimus—MTOR—liver—sarcoma	0.000864	0.00661	CbGeAlD
Tacrolimus—FKBP1A—testis—sarcoma	0.000822	0.00629	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—liver—sarcoma	0.000817	0.00625	CbGeAlD
Tacrolimus—FKBP1A—liver—sarcoma	0.000777	0.00595	CbGeAlD
Tacrolimus—ORM1—bone marrow—sarcoma	0.000753	0.00576	CbGeAlD
Tacrolimus—MTOR—lymph node—sarcoma	0.000662	0.00507	CbGeAlD
Tacrolimus—CYP3A5—hematopoietic system—sarcoma	0.000653	0.005	CbGeAlD
Tacrolimus—ORM1—liver—sarcoma	0.000608	0.00465	CbGeAlD
Tacrolimus—FKBP1A—lymph node—sarcoma	0.000596	0.00456	CbGeAlD
Tacrolimus—ALB—testis—sarcoma	0.000564	0.00432	CbGeAlD
Tacrolimus—ALB—liver—sarcoma	0.000533	0.00408	CbGeAlD
Tacrolimus—CYP3A4—hematopoietic system—sarcoma	0.00049	0.00375	CbGeAlD
Tacrolimus—ORM1—lymph node—sarcoma	0.000466	0.00357	CbGeAlD
Tacrolimus—ALB—lymph node—sarcoma	0.000409	0.00313	CbGeAlD
Tacrolimus—ABCB1—myometrium—sarcoma	0.000404	0.00309	CbGeAlD
Tacrolimus—ABCB1—embryo—sarcoma	0.000389	0.00297	CbGeAlD
Tacrolimus—ABCB1—seminal vesicle—sarcoma	0.000365	0.00279	CbGeAlD
Tacrolimus—ABCB1—hematopoietic system—sarcoma	0.000347	0.00265	CbGeAlD
Tacrolimus—CYP3A5—liver—sarcoma	0.000338	0.00259	CbGeAlD
Tacrolimus—ABCB1—uterus—sarcoma	0.000262	0.00201	CbGeAlD
Tacrolimus—CYP3A4—liver—sarcoma	0.000254	0.00194	CbGeAlD
Tacrolimus—ABCB1—lymphoid tissue—sarcoma	0.000244	0.00187	CbGeAlD
Tacrolimus—ABCB1—bone marrow—sarcoma	0.000222	0.0017	CbGeAlD
Tacrolimus—ABCB1—testis—sarcoma	0.00019	0.00145	CbGeAlD
Tacrolimus—ABCB1—liver—sarcoma	0.00018	0.00138	CbGeAlD
Tacrolimus—ABCB1—lymph node—sarcoma	0.000138	0.00105	CbGeAlD
Tacrolimus—Renal failure—Epirubicin—sarcoma	0.000114	0.000353	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Etoposide—sarcoma	0.000114	0.000353	CcSEcCtD
Tacrolimus—Asthenia—Mitoxantrone—sarcoma	0.000114	0.000352	CcSEcCtD
Tacrolimus—Fatigue—Etoposide—sarcoma	0.000114	0.000352	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Epirubicin—sarcoma	0.000114	0.000352	CcSEcCtD
Tacrolimus—Stomatitis—Epirubicin—sarcoma	0.000113	0.00035	CcSEcCtD
Tacrolimus—Jaundice—Epirubicin—sarcoma	0.000113	0.00035	CcSEcCtD
Tacrolimus—Constipation—Etoposide—sarcoma	0.000113	0.000349	CcSEcCtD
Tacrolimus—Pain—Etoposide—sarcoma	0.000113	0.000349	CcSEcCtD
Tacrolimus—Conjunctivitis—Epirubicin—sarcoma	0.000113	0.000349	CcSEcCtD
Tacrolimus—Urinary tract infection—Epirubicin—sarcoma	0.000113	0.000349	CcSEcCtD
Tacrolimus—Neutropenia—Doxorubicin—sarcoma	0.000112	0.000348	CcSEcCtD
Tacrolimus—Dysuria—Doxorubicin—sarcoma	0.000112	0.000348	CcSEcCtD
Tacrolimus—Diarrhoea—Vincristine—sarcoma	0.000111	0.000345	CcSEcCtD
Tacrolimus—Sweating—Epirubicin—sarcoma	0.000111	0.000344	CcSEcCtD
Tacrolimus—Pollakiuria—Doxorubicin—sarcoma	0.000111	0.000344	CcSEcCtD
Tacrolimus—Haematuria—Epirubicin—sarcoma	0.00011	0.000342	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Doxorubicin—sarcoma	0.00011	0.00034	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Epirubicin—sarcoma	0.00011	0.00034	CcSEcCtD
Tacrolimus—Weight increased—Doxorubicin—sarcoma	0.000109	0.000339	CcSEcCtD
Tacrolimus—Epistaxis—Epirubicin—sarcoma	0.000109	0.000339	CcSEcCtD
Tacrolimus—Nausea—Thiotepa—sarcoma	0.000109	0.000338	CcSEcCtD
Tacrolimus—Weight decreased—Doxorubicin—sarcoma	0.000109	0.000337	CcSEcCtD
Tacrolimus—Sinusitis—Epirubicin—sarcoma	0.000109	0.000337	CcSEcCtD
Tacrolimus—Feeling abnormal—Etoposide—sarcoma	0.000109	0.000337	CcSEcCtD
Tacrolimus—Hyperglycaemia—Doxorubicin—sarcoma	0.000108	0.000336	CcSEcCtD
Tacrolimus—Diarrhoea—Mitoxantrone—sarcoma	0.000108	0.000336	CcSEcCtD
Tacrolimus—Nausea—Dactinomycin—sarcoma	0.000108	0.000335	CcSEcCtD
Tacrolimus—Agranulocytosis—Epirubicin—sarcoma	0.000108	0.000335	CcSEcCtD
Tacrolimus—Pneumonia—Doxorubicin—sarcoma	0.000108	0.000334	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Etoposide—sarcoma	0.000108	0.000334	CcSEcCtD
Tacrolimus—Dizziness—Vincristine—sarcoma	0.000108	0.000333	CcSEcCtD
Tacrolimus—Infestation NOS—Doxorubicin—sarcoma	0.000107	0.000332	CcSEcCtD
Tacrolimus—Infestation—Doxorubicin—sarcoma	0.000107	0.000332	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000106	0.000329	CcSEcCtD
Tacrolimus—Bradycardia—Epirubicin—sarcoma	0.000106	0.000328	CcSEcCtD
Tacrolimus—Renal failure—Doxorubicin—sarcoma	0.000105	0.000327	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Doxorubicin—sarcoma	0.000105	0.000326	CcSEcCtD
Tacrolimus—Urticaria—Etoposide—sarcoma	0.000105	0.000324	CcSEcCtD
Tacrolimus—Haemoglobin—Epirubicin—sarcoma	0.000105	0.000324	CcSEcCtD
Tacrolimus—Stomatitis—Doxorubicin—sarcoma	0.000104	0.000324	CcSEcCtD
Tacrolimus—Jaundice—Doxorubicin—sarcoma	0.000104	0.000324	CcSEcCtD
Tacrolimus—Rhinitis—Epirubicin—sarcoma	0.000104	0.000323	CcSEcCtD
Tacrolimus—Abdominal pain—Etoposide—sarcoma	0.000104	0.000323	CcSEcCtD
Tacrolimus—Body temperature increased—Etoposide—sarcoma	0.000104	0.000323	CcSEcCtD
Tacrolimus—Urinary tract infection—Doxorubicin—sarcoma	0.000104	0.000323	CcSEcCtD
Tacrolimus—Conjunctivitis—Doxorubicin—sarcoma	0.000104	0.000323	CcSEcCtD
Tacrolimus—Haemorrhage—Epirubicin—sarcoma	0.000104	0.000322	CcSEcCtD
Tacrolimus—Hepatitis—Epirubicin—sarcoma	0.000104	0.000322	CcSEcCtD
Tacrolimus—Hypoaesthesia—Epirubicin—sarcoma	0.000103	0.000321	CcSEcCtD
Tacrolimus—Vomiting—Vincristine—sarcoma	0.000103	0.000321	CcSEcCtD
Tacrolimus—Pharyngitis—Epirubicin—sarcoma	0.000103	0.00032	CcSEcCtD
Tacrolimus—Sweating—Doxorubicin—sarcoma	0.000103	0.000318	CcSEcCtD
Tacrolimus—Urinary tract disorder—Epirubicin—sarcoma	0.000103	0.000318	CcSEcCtD
Tacrolimus—Rash—Vincristine—sarcoma	0.000103	0.000318	CcSEcCtD
Tacrolimus—Dermatitis—Vincristine—sarcoma	0.000102	0.000318	CcSEcCtD
Tacrolimus—Oedema peripheral—Epirubicin—sarcoma	0.000102	0.000317	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—sarcoma	0.000102	0.000317	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—sarcoma	0.000102	0.000317	CcSEcCtD
Tacrolimus—Urethral disorder—Epirubicin—sarcoma	0.000102	0.000316	CcSEcCtD
Tacrolimus—Headache—Vincristine—sarcoma	0.000102	0.000316	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Doxorubicin—sarcoma	0.000101	0.000314	CcSEcCtD
Tacrolimus—Epistaxis—Doxorubicin—sarcoma	0.000101	0.000313	CcSEcCtD
Tacrolimus—Vomiting—Mitoxantrone—sarcoma	0.000101	0.000312	CcSEcCtD
Tacrolimus—Sinusitis—Doxorubicin—sarcoma	0.000101	0.000312	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—sarcoma	0.0001	0.000311	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—sarcoma	0.0001	0.00031	CcSEcCtD
Tacrolimus—Rash—Mitoxantrone—sarcoma	9.99e-05	0.00031	CcSEcCtD
Tacrolimus—Dermatitis—Mitoxantrone—sarcoma	9.98e-05	0.000309	CcSEcCtD
Tacrolimus—Headache—Mitoxantrone—sarcoma	9.93e-05	0.000308	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—sarcoma	9.83e-05	0.000305	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—sarcoma	9.8e-05	0.000304	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—sarcoma	9.72e-05	0.000301	CcSEcCtD
Tacrolimus—Hypersensitivity—Etoposide—sarcoma	9.71e-05	0.000301	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—sarcoma	9.7e-05	0.0003	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—sarcoma	9.67e-05	0.0003	CcSEcCtD
Tacrolimus—Nausea—Vincristine—sarcoma	9.66e-05	0.000299	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—sarcoma	9.65e-05	0.000299	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—sarcoma	9.65e-05	0.000299	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—sarcoma	9.65e-05	0.000299	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—sarcoma	9.62e-05	0.000298	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—sarcoma	9.62e-05	0.000298	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—sarcoma	9.57e-05	0.000297	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—sarcoma	9.55e-05	0.000296	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—sarcoma	9.5e-05	0.000294	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—sarcoma	9.48e-05	0.000294	CcSEcCtD
Tacrolimus—Asthenia—Etoposide—sarcoma	9.46e-05	0.000293	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—sarcoma	9.46e-05	0.000293	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—sarcoma	9.44e-05	0.000292	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—sarcoma	9.43e-05	0.000292	CcSEcCtD
Tacrolimus—Nausea—Mitoxantrone—sarcoma	9.41e-05	0.000292	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—sarcoma	9.39e-05	0.000291	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—sarcoma	9.37e-05	0.00029	CcSEcCtD
Tacrolimus—Chills—Epirubicin—sarcoma	9.33e-05	0.000289	CcSEcCtD
Tacrolimus—Pruritus—Etoposide—sarcoma	9.33e-05	0.000289	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—sarcoma	9.29e-05	0.000288	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—sarcoma	9.27e-05	0.000287	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—sarcoma	9.19e-05	0.000285	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—sarcoma	9.11e-05	0.000282	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—sarcoma	9.1e-05	0.000282	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—sarcoma	9.05e-05	0.000281	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—sarcoma	9.05e-05	0.000281	CcSEcCtD
Tacrolimus—Diarrhoea—Etoposide—sarcoma	9.02e-05	0.000279	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—sarcoma	8.99e-05	0.000279	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—sarcoma	8.97e-05	0.000278	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—sarcoma	8.93e-05	0.000277	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—sarcoma	8.93e-05	0.000277	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—sarcoma	8.92e-05	0.000276	CcSEcCtD
Tacrolimus—Tension—Epirubicin—sarcoma	8.88e-05	0.000275	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—sarcoma	8.87e-05	0.000275	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—sarcoma	8.79e-05	0.000272	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—sarcoma	8.76e-05	0.000271	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—sarcoma	8.73e-05	0.000271	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—sarcoma	8.72e-05	0.00027	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—sarcoma	8.7e-05	0.00027	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—sarcoma	8.69e-05	0.000269	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—sarcoma	8.67e-05	0.000269	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—sarcoma	8.63e-05	0.000268	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—sarcoma	8.6e-05	0.000266	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—sarcoma	8.53e-05	0.000264	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—sarcoma	8.5e-05	0.000263	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—sarcoma	8.43e-05	0.000261	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—sarcoma	8.4e-05	0.00026	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—sarcoma	8.38e-05	0.00026	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—sarcoma	8.38e-05	0.00026	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—sarcoma	8.38e-05	0.00026	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—sarcoma	8.37e-05	0.000259	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—sarcoma	8.32e-05	0.000258	CcSEcCtD
Tacrolimus—Rash—Etoposide—sarcoma	8.31e-05	0.000258	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—sarcoma	8.3e-05	0.000257	CcSEcCtD
Tacrolimus—Headache—Etoposide—sarcoma	8.26e-05	0.000256	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—sarcoma	8.25e-05	0.000256	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—sarcoma	8.22e-05	0.000255	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—sarcoma	8.2e-05	0.000254	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—sarcoma	8.16e-05	0.000253	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—sarcoma	8.14e-05	0.000252	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—sarcoma	8.13e-05	0.000252	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—sarcoma	8.12e-05	0.000252	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—sarcoma	8.1e-05	0.000251	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—sarcoma	8.1e-05	0.000251	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—sarcoma	8.05e-05	0.00025	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—sarcoma	8e-05	0.000248	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—sarcoma	7.96e-05	0.000247	CcSEcCtD
Tacrolimus—Cough—Epirubicin—sarcoma	7.9e-05	0.000245	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—sarcoma	7.89e-05	0.000245	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—sarcoma	7.84e-05	0.000243	CcSEcCtD
Tacrolimus—Nausea—Etoposide—sarcoma	7.83e-05	0.000243	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—sarcoma	7.82e-05	0.000242	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—sarcoma	7.77e-05	0.000241	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—sarcoma	7.74e-05	0.00024	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—sarcoma	7.71e-05	0.000239	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—sarcoma	7.71e-05	0.000239	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—sarcoma	7.71e-05	0.000239	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—sarcoma	7.7e-05	0.000239	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—sarcoma	7.68e-05	0.000238	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	7.65e-05	0.000237	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—sarcoma	7.61e-05	0.000236	CcSEcCtD
Tacrolimus—MTOR—Disease—NPM1—sarcoma	7.56e-05	0.000534	CbGpPWpGaD
Tacrolimus—Malaise—Doxorubicin—sarcoma	7.55e-05	0.000234	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—sarcoma	7.54e-05	0.000234	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—sarcoma	7.53e-05	0.000233	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	7.52e-05	0.000532	CbGpPWpGaD
Tacrolimus—Syncope—Doxorubicin—sarcoma	7.51e-05	0.000233	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	7.51e-05	0.000531	CbGpPWpGaD
Tacrolimus—Leukopenia—Doxorubicin—sarcoma	7.5e-05	0.000232	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—KIT—sarcoma	7.46e-05	0.000527	CbGpPWpGaD
Tacrolimus—Confusional state—Epirubicin—sarcoma	7.45e-05	0.000231	CcSEcCtD
Tacrolimus—MTOR—Signaling by SCF-KIT—HRAS—sarcoma	7.45e-05	0.000527	CbGpPWpGaD
Tacrolimus—Palpitations—Doxorubicin—sarcoma	7.4e-05	0.000229	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—sarcoma	7.39e-05	0.000229	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—sarcoma	7.39e-05	0.000229	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—sarcoma	7.37e-05	0.000521	CbGpPWpGaD
Tacrolimus—Loss of consciousness—Doxorubicin—sarcoma	7.36e-05	0.000228	CcSEcCtD
Tacrolimus—Infection—Epirubicin—sarcoma	7.34e-05	0.000227	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—FOXO1—sarcoma	7.33e-05	0.000518	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—HRAS—sarcoma	7.33e-05	0.000518	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PDGFRB—sarcoma	7.31e-05	0.000517	CbGpPWpGaD
Tacrolimus—Cough—Doxorubicin—sarcoma	7.31e-05	0.000227	CcSEcCtD
Tacrolimus—MTOR—Signaling by FGFR in disease—KRAS—sarcoma	7.31e-05	0.000517	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	7.31e-05	0.000517	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KRAS—sarcoma	7.31e-05	0.000517	CbGpPWpGaD
Tacrolimus—Shock—Epirubicin—sarcoma	7.27e-05	0.000225	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—sarcoma	7.26e-05	0.000225	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—sarcoma	7.25e-05	0.000225	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—KRAS—sarcoma	7.24e-05	0.000512	CbGpPWpGaD
Tacrolimus—Thrombocytopenia—Epirubicin—sarcoma	7.23e-05	0.000224	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—sarcoma	7.23e-05	0.000224	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—sarcoma	7.21e-05	0.000223	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—PDGFRA—sarcoma	7.2e-05	0.000509	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KRAS—sarcoma	7.18e-05	0.000507	CbGpPWpGaD
Tacrolimus—Skin disorder—Epirubicin—sarcoma	7.18e-05	0.000222	CcSEcCtD
Tacrolimus—ALB—Hemostasis—VEGFC—sarcoma	7.17e-05	0.000507	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—EGFR—sarcoma	7.16e-05	0.000506	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—KRAS—sarcoma	7.15e-05	0.000505	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—JUN—sarcoma	7.14e-05	0.000505	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Epirubicin—sarcoma	7.14e-05	0.000221	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—sarcoma	7.13e-05	0.000221	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—sarcoma	7.13e-05	0.000221	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—sarcoma	7.13e-05	0.000221	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—sarcoma	7.13e-05	0.000504	CbGpPWpGaD
Tacrolimus—Anxiety—Doxorubicin—sarcoma	7.11e-05	0.00022	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—CREB1—sarcoma	7.1e-05	0.000502	CbGpPWpGaD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	7.08e-05	0.000219	CcSEcCtD
Tacrolimus—ABCB1—Allograft Rejection—VEGFA—sarcoma	7.05e-05	0.000499	CbGpPWpGaD
Tacrolimus—Discomfort—Doxorubicin—sarcoma	7.05e-05	0.000218	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—sarcoma	7.04e-05	0.000218	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—FOXO1—sarcoma	7.04e-05	0.000498	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FLT1—sarcoma	7.03e-05	0.000497	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—sarcoma	7.02e-05	0.000497	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PDGFRB—sarcoma	7.02e-05	0.000497	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—HRAS—sarcoma	7.01e-05	0.000496	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—FOXO1—sarcoma	7.01e-05	0.000495	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PDGFRB—sarcoma	6.99e-05	0.000495	CbGpPWpGaD
Tacrolimus—Dry mouth—Doxorubicin—sarcoma	6.97e-05	0.000216	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—PLCG1—sarcoma	6.91e-05	0.000489	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PDGFRA—sarcoma	6.91e-05	0.000489	CbGpPWpGaD
Tacrolimus—Hypotension—Epirubicin—sarcoma	6.9e-05	0.000214	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—sarcoma	6.89e-05	0.000214	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—EGFR—sarcoma	6.89e-05	0.000487	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KIT—sarcoma	6.89e-05	0.000487	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PDGFRA—sarcoma	6.89e-05	0.000487	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	6.85e-05	0.000484	CbGpPWpGaD
Tacrolimus—Oedema—Doxorubicin—sarcoma	6.84e-05	0.000212	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—sarcoma	6.84e-05	0.000212	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—sarcoma	6.79e-05	0.00021	CcSEcCtD
Tacrolimus—MTOR—B Cell Activation—KRAS—sarcoma	6.76e-05	0.000478	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—HRAS—sarcoma	6.73e-05	0.000476	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—sarcoma	6.73e-05	0.000209	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—sarcoma	6.73e-05	0.000208	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—sarcoma	6.7e-05	0.000208	CcSEcCtD
Tacrolimus—MTOR—Downstream signal transduction—HRAS—sarcoma	6.7e-05	0.000474	CbGpPWpGaD
Tacrolimus—Thrombocytopenia—Doxorubicin—sarcoma	6.69e-05	0.000207	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—sarcoma	6.68e-05	0.000207	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—sarcoma	6.67e-05	0.000207	CcSEcCtD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—sarcoma	6.67e-05	0.000471	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—HRAS—sarcoma	6.67e-05	0.000471	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IGF1R—sarcoma	6.65e-05	0.00047	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCR4—sarcoma	6.64e-05	0.00047	CbGpPWpGaD
Tacrolimus—Skin disorder—Doxorubicin—sarcoma	6.64e-05	0.000206	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—sarcoma	6.63e-05	0.000206	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB2—HRAS—sarcoma	6.63e-05	0.000469	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Doxorubicin—sarcoma	6.61e-05	0.000205	CcSEcCtD
Tacrolimus—MTOR—DAP12 signaling—HRAS—sarcoma	6.6e-05	0.000467	CbGpPWpGaD
Tacrolimus—Dyspnoea—Epirubicin—sarcoma	6.59e-05	0.000204	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—ATF1—sarcoma	6.57e-05	0.000465	CbGpPWpGaD
Tacrolimus—Somnolence—Epirubicin—sarcoma	6.57e-05	0.000204	CcSEcCtD
Tacrolimus—PPP3CA—Disease—CREB1—sarcoma	6.55e-05	0.000463	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ENO2—sarcoma	6.55e-05	0.000463	CbGpPWpGaD
Tacrolimus—Anorexia—Doxorubicin—sarcoma	6.52e-05	0.000202	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—KRAS—sarcoma	6.51e-05	0.00046	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	6.51e-05	0.00046	CbGpPWpGaD
Tacrolimus—Dyspepsia—Epirubicin—sarcoma	6.5e-05	0.000202	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	6.47e-05	0.000458	CbGpPWpGaD
Tacrolimus—Decreased appetite—Epirubicin—sarcoma	6.42e-05	0.000199	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—sarcoma	6.39e-05	0.000198	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—sarcoma	6.38e-05	0.000198	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—sarcoma	6.37e-05	0.000197	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—FOXO1—sarcoma	6.33e-05	0.000447	CbGpPWpGaD
Tacrolimus—Pain—Epirubicin—sarcoma	6.32e-05	0.000196	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—sarcoma	6.32e-05	0.000196	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—PDGFRB—sarcoma	6.32e-05	0.000447	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—VEGFA—sarcoma	6.24e-05	0.000441	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—sarcoma	6.23e-05	0.000193	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—PDGFRA—sarcoma	6.22e-05	0.00044	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	6.21e-05	0.000439	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—HRAS—sarcoma	6.21e-05	0.000439	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HRAS—sarcoma	6.21e-05	0.000439	CbGpPWpGaD
Tacrolimus—Insomnia—Doxorubicin—sarcoma	6.18e-05	0.000192	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—HRAS—sarcoma	6.15e-05	0.000435	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTPRC—sarcoma	6.15e-05	0.000435	CbGpPWpGaD
Tacrolimus—Paraesthesia—Doxorubicin—sarcoma	6.14e-05	0.00019	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—sarcoma	6.1e-05	0.000431	CbGpPWpGaD
Tacrolimus—Dyspnoea—Doxorubicin—sarcoma	6.09e-05	0.000189	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—sarcoma	6.09e-05	0.000189	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—sarcoma	6.08e-05	0.000188	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—HRAS—sarcoma	6.07e-05	0.000429	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Epirubicin—sarcoma	6.04e-05	0.000187	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—sarcoma	6.02e-05	0.000186	CcSEcCtD
Tacrolimus—MTOR—Immune System—PLCG1—sarcoma	6.02e-05	0.000425	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—SRC—sarcoma	6.01e-05	0.000425	CbGpPWpGaD
Tacrolimus—Decreased appetite—Doxorubicin—sarcoma	5.94e-05	0.000184	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—sarcoma	5.9e-05	0.000183	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—sarcoma	5.89e-05	0.000183	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—MDM2—sarcoma	5.87e-05	0.000415	CbGpPWpGaD
Tacrolimus—Urticaria—Epirubicin—sarcoma	5.87e-05	0.000182	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—TLE1—sarcoma	5.87e-05	0.000415	CbGpPWpGaD
Tacrolimus—Constipation—Doxorubicin—sarcoma	5.85e-05	0.000181	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—sarcoma	5.85e-05	0.000181	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—sarcoma	5.84e-05	0.000181	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—sarcoma	5.84e-05	0.000181	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—NRAS—sarcoma	5.78e-05	0.000409	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—HRAS—sarcoma	5.75e-05	0.000406	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2—sarcoma	5.74e-05	0.000406	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ATF1—sarcoma	5.71e-05	0.000404	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PLCG1—sarcoma	5.64e-05	0.000399	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Doxorubicin—sarcoma	5.63e-05	0.000175	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—sarcoma	5.59e-05	0.000173	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—KIT—sarcoma	5.58e-05	0.000395	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PLCG1—sarcoma	5.55e-05	0.000393	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	5.54e-05	0.000392	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HRAS—sarcoma	5.53e-05	0.000391	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	5.5e-05	0.000389	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Epirubicin—sarcoma	5.44e-05	0.000169	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—sarcoma	5.43e-05	0.000168	CcSEcCtD
Tacrolimus—PPP3CA—Disease—MDM2—sarcoma	5.42e-05	0.000383	CbGpPWpGaD
Tacrolimus—Body temperature increased—Doxorubicin—sarcoma	5.4e-05	0.000167	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—sarcoma	5.4e-05	0.000167	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—KIT—sarcoma	5.36e-05	0.000379	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KIT—sarcoma	5.34e-05	0.000378	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CXCR4—sarcoma	5.34e-05	0.000377	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CREB1—sarcoma	5.31e-05	0.000376	CbGpPWpGaD
Tacrolimus—Asthenia—Epirubicin—sarcoma	5.3e-05	0.000164	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—EGFR—sarcoma	5.27e-05	0.000373	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2—sarcoma	5.25e-05	0.000371	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KDR—sarcoma	5.23e-05	0.00037	CbGpPWpGaD
Tacrolimus—Pruritus—Epirubicin—sarcoma	5.23e-05	0.000162	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—IGF1R—sarcoma	5.15e-05	0.000365	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—JUN—sarcoma	5.11e-05	0.000361	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CREB1—sarcoma	5.1e-05	0.000361	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CREB1—sarcoma	5.08e-05	0.000359	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CTNNB1—sarcoma	5.07e-05	0.000358	CbGpPWpGaD
Tacrolimus—Diarrhoea—Epirubicin—sarcoma	5.06e-05	0.000157	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—sarcoma	5.04e-05	0.000156	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—KRAS—sarcoma	4.98e-05	0.000352	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFC—sarcoma	4.95e-05	0.00035	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FOXO1—sarcoma	4.91e-05	0.000347	CbGpPWpGaD
Tacrolimus—Asthenia—Doxorubicin—sarcoma	4.9e-05	0.000152	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—PDGFRB—sarcoma	4.9e-05	0.000346	CbGpPWpGaD
Tacrolimus—Dizziness—Epirubicin—sarcoma	4.89e-05	0.000151	CcSEcCtD
Tacrolimus—Pruritus—Doxorubicin—sarcoma	4.84e-05	0.00015	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—PDGFRA—sarcoma	4.82e-05	0.000341	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KIT—sarcoma	4.82e-05	0.000341	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—NRAS—sarcoma	4.82e-05	0.000341	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—sarcoma	4.72e-05	0.000333	CbGpPWpGaD
Tacrolimus—Vomiting—Epirubicin—sarcoma	4.7e-05	0.000146	CcSEcCtD
Tacrolimus—PPP3CA—Disease—CTNNB1—sarcoma	4.68e-05	0.000331	CbGpPWpGaD
Tacrolimus—Diarrhoea—Doxorubicin—sarcoma	4.68e-05	0.000145	CcSEcCtD
Tacrolimus—Rash—Epirubicin—sarcoma	4.66e-05	0.000144	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—sarcoma	4.65e-05	0.000144	CcSEcCtD
Tacrolimus—Headache—Epirubicin—sarcoma	4.63e-05	0.000143	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CREB1—sarcoma	4.59e-05	0.000325	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.58e-05	0.000324	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—SRC—sarcoma	4.58e-05	0.000324	CbGpPWpGaD
Tacrolimus—Dizziness—Doxorubicin—sarcoma	4.52e-05	0.00014	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—NRAS—sarcoma	4.41e-05	0.000312	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MDM2—sarcoma	4.4e-05	0.000311	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EGFR—sarcoma	4.39e-05	0.000311	CbGpPWpGaD
Tacrolimus—Nausea—Epirubicin—sarcoma	4.39e-05	0.000136	CcSEcCtD
Tacrolimus—Vomiting—Doxorubicin—sarcoma	4.35e-05	0.000135	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—ENO2—sarcoma	4.33e-05	0.000306	CbGpPWpGaD
Tacrolimus—Rash—Doxorubicin—sarcoma	4.31e-05	0.000134	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—sarcoma	4.31e-05	0.000133	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—HBA1—sarcoma	4.3e-05	0.000304	CbGpPWpGaD
Tacrolimus—Headache—Doxorubicin—sarcoma	4.28e-05	0.000133	CcSEcCtD
Tacrolimus—MTOR—Immune System—FOXO1—sarcoma	4.27e-05	0.000302	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PDGFRB—sarcoma	4.26e-05	0.000301	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—HRAS—sarcoma	4.23e-05	0.000299	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—SRC—sarcoma	4.23e-05	0.000299	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—MDM2—sarcoma	4.22e-05	0.000299	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MDM2—sarcoma	4.2e-05	0.000297	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PDGFRA—sarcoma	4.19e-05	0.000297	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	4.16e-05	0.000294	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—KRAS—sarcoma	4.15e-05	0.000293	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NRAS—sarcoma	4.07e-05	0.000288	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—sarcoma	4.06e-05	0.000126	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—KDR—sarcoma	4.06e-05	0.000287	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—sarcoma	4.01e-05	0.000284	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.99e-05	0.000282	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.98e-05	0.000282	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FLT1—sarcoma	3.96e-05	0.00028	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.95e-05	0.00028	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FOXO1—sarcoma	3.94e-05	0.000279	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PDGFRB—sarcoma	3.93e-05	0.000278	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PLCG1—sarcoma	3.89e-05	0.000275	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PDGFRA—sarcoma	3.87e-05	0.000274	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—JUN—sarcoma	3.82e-05	0.00027	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MDM2—sarcoma	3.8e-05	0.000269	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CTNNB1—sarcoma	3.79e-05	0.000268	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KRAS—sarcoma	3.79e-05	0.000268	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MYC—sarcoma	3.79e-05	0.000268	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KIT—sarcoma	3.74e-05	0.000264	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCR4—sarcoma	3.74e-05	0.000264	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—sarcoma	3.71e-05	0.000262	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ATF1—sarcoma	3.69e-05	0.000261	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PLCG1—sarcoma	3.67e-05	0.00026	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	3.63e-05	0.000257	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CTNNB1—sarcoma	3.63e-05	0.000256	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.57e-05	0.000253	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CREB1—sarcoma	3.56e-05	0.000252	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	3.54e-05	0.00025	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—sarcoma	3.53e-05	0.000249	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KRAS—sarcoma	3.5e-05	0.000248	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.48e-05	0.000246	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—SRC—sarcoma	3.43e-05	0.000242	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2—sarcoma	3.39e-05	0.00024	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCND1—sarcoma	3.31e-05	0.000234	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—JUN—sarcoma	3.3e-05	0.000233	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—sarcoma	3.3e-05	0.000233	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—SRC—sarcoma	3.29e-05	0.000233	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SRC—sarcoma	3.28e-05	0.000232	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CTNNB1—sarcoma	3.28e-05	0.000232	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KIT—sarcoma	3.25e-05	0.00023	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—sarcoma	3.22e-05	0.000228	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	3.2e-05	0.000226	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—sarcoma	3.17e-05	0.000224	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—sarcoma	3.15e-05	0.000223	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	3.13e-05	0.000222	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ENO2—sarcoma	3.13e-05	0.000221	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HBA1—sarcoma	3.11e-05	0.00022	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CREB1—sarcoma	3.1e-05	0.000219	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—sarcoma	3.01e-05	0.000212	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KIT—sarcoma	3e-05	0.000212	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—sarcoma	2.98e-05	0.00021	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SRC—sarcoma	2.96e-05	0.000209	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.96e-05	0.000209	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MDM2—sarcoma	2.94e-05	0.000208	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—sarcoma	2.94e-05	0.000208	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1R—sarcoma	2.9e-05	0.000205	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—sarcoma	2.89e-05	0.000204	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—sarcoma	2.88e-05	0.000204	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—sarcoma	2.87e-05	0.000203	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CREB1—sarcoma	2.86e-05	0.000202	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—sarcoma	2.85e-05	0.000201	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—sarcoma	2.84e-05	0.000201	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FOXO1—sarcoma	2.76e-05	0.000195	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PDGFRB—sarcoma	2.75e-05	0.000195	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—sarcoma	2.73e-05	0.000193	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—sarcoma	2.71e-05	0.000192	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PDGFRA—sarcoma	2.71e-05	0.000192	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ENO2—sarcoma	2.69e-05	0.00019	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HBA1—sarcoma	2.68e-05	0.000189	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PLCG1—sarcoma	2.65e-05	0.000188	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—sarcoma	2.65e-05	0.000188	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—sarcoma	2.63e-05	0.000186	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.63e-05	0.000186	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—sarcoma	2.59e-05	0.000183	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—sarcoma	2.56e-05	0.000181	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MDM2—sarcoma	2.56e-05	0.000181	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—JUN—sarcoma	2.56e-05	0.000181	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CTNNB1—sarcoma	2.54e-05	0.00018	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—sarcoma	2.45e-05	0.000173	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—sarcoma	2.41e-05	0.000171	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MDM2—sarcoma	2.36e-05	0.000167	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO2—sarcoma	2.36e-05	0.000167	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HBA1—sarcoma	2.34e-05	0.000166	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—sarcoma	2.32e-05	0.000164	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—sarcoma	2.31e-05	0.000163	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SRC—sarcoma	2.3e-05	0.000162	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—sarcoma	2.29e-05	0.000162	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PLCG1—sarcoma	2.29e-05	0.000162	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KDR—sarcoma	2.28e-05	0.000161	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—sarcoma	2.24e-05	0.000158	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—JUN—sarcoma	2.23e-05	0.000157	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTNNB1—sarcoma	2.21e-05	0.000156	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—sarcoma	2.21e-05	0.000156	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—sarcoma	2.18e-05	0.000154	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—sarcoma	2.14e-05	0.000152	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KIT—sarcoma	2.1e-05	0.000149	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—sarcoma	2.08e-05	0.000147	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—sarcoma	2.06e-05	0.000145	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CTNNB1—sarcoma	2.04e-05	0.000144	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—sarcoma	2.01e-05	0.000142	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PLCG1—sarcoma	2e-05	0.000142	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CREB1—sarcoma	2e-05	0.000142	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SRC—sarcoma	2e-05	0.000141	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—sarcoma	1.92e-05	0.000136	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—sarcoma	1.9e-05	0.000134	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SRC—sarcoma	1.87e-05	0.000132	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SRC—sarcoma	1.84e-05	0.00013	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—sarcoma	1.82e-05	0.000129	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—sarcoma	1.8e-05	0.000127	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—sarcoma	1.77e-05	0.000125	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—sarcoma	1.75e-05	0.000124	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—sarcoma	1.69e-05	0.000119	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MDM2—sarcoma	1.66e-05	0.000117	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—sarcoma	1.65e-05	0.000117	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—sarcoma	1.65e-05	0.000117	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—sarcoma	1.62e-05	0.000114	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—sarcoma	1.62e-05	0.000114	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—sarcoma	1.55e-05	0.00011	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—sarcoma	1.53e-05	0.000108	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—sarcoma	1.48e-05	0.000105	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO2—sarcoma	1.45e-05	0.000103	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HBA1—sarcoma	1.44e-05	0.000102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—sarcoma	1.44e-05	0.000102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JUN—sarcoma	1.44e-05	0.000102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNB1—sarcoma	1.43e-05	0.000101	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—sarcoma	1.41e-05	9.94e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—sarcoma	1.38e-05	9.74e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—sarcoma	1.32e-05	9.31e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—sarcoma	1.3e-05	9.18e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SRC—sarcoma	1.29e-05	9.13e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—sarcoma	1.26e-05	8.89e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—sarcoma	1.24e-05	8.78e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLCG1—sarcoma	1.23e-05	8.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—sarcoma	1.16e-05	8.18e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—sarcoma	1.13e-05	8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—sarcoma	1.07e-05	7.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—sarcoma	9.5e-06	6.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—sarcoma	9.09e-06	6.43e-05	CbGpPWpGaD
